$TEM

LEFKOFSKY ERIC P sold $10.5M of TEM (indirect holdings)

LEFKOFSKY ERIC P (CEO and Chairman) sold 250,000 indirectly-held shares of Tempus AI, Inc. (TEM) at an average of $42.06 ($41.34–$42.95, $10.51M total) across 12 trades on 2026-07-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · LEFKOFSKY ERIC P
Published Jul 31, 2026, 1:42 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 31, 2026, 2:02 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$TEM
Neutral
medium confidence
Mentioned
$TEM
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEMNeutralLow
01

Why it matters

The newest actionable element is the disclosed sale size ($10.51M) and post-transaction holdings (200,000 shares). The 10b5-1 designation suggests the trades were scheduled in advance, which typically dampens inference about near-term fundamentals.

02

Market read

This is a primary insider-selling disclosure that may influence short-term sentiment, but it is less likely to drive a fundamental repricing due to the pre-arranged 10b5-1 plan.

03

What to watch

Traders may over-weight insider sales; the key nuance is that the plan was pre-arranged, and the filing does not provide new operational or financial guidance.

Relevance 6/10Novelty 5/10Timing: filed 2026-07-30 for a 2026-07-28 sale

Background

The article is an SEC Form 4 insider transaction disclosure for Tempus AI, Inc. (TEM) by CEO and Chairman Eric P. Lefkofsky, with the sale executed across multiple trades on 2026-07-28.

Company-level read

Ticker impact

$TEMNeutralMedium confidence
Context

Tempus AI CEO and Chairman sold $10.51M of TEM shares via a 10b5-1 plan, leaving 200,000 shares after the sale.

Expected impact

Low to modest near-term sentiment impact; directionally mixed and likely limited given 10b5-1 pre-arrangement.

Evidence & confidence

The filing is a primary Form 4 disclosure with transaction size ($10.5M) and timing (2026-07-28), but it explicitly states a pre-arranged 10b5-1 plan, which reduces interpretability as new negative information.

Market effects

Limited sector read-through; this is company-specific insider selling rather than a sector-wide regulatory or demand signal.

No clear regional spillover indicated by the filing details.

No global market linkage beyond Tempus AI-specific sentiment.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect routine liquidity planning rather than bearish expectations, so price impact could be negligible.

Key entities

  • Tempus AI, Inc.

    Subject of the Form 4 insider transaction; CEO and Chairman sold shares under a 10b5-1 plan.

  • LEFKOFSKY ERIC P

    CEO and Chairman, reported indirect open-market sale totaling $10.51M across 12 trades.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TEMMedAI 9/10

Tempus AI (TEM) Jumped on Moderna’s Melanoma Win. Did its $1.5B Personalis Acquisition Just Get Validated?

Tempus AI (TEM) shares rose after Moderna and Merck reported positive Phase 3 trial results for a personalized cancer therapy, validating Personalis' sequencing technology. Tempus agreed to acquire Personalis for $1.5B, with the deal pending. Personalis' technology is distinct from the main target of the acquisition, NeXT Personal, a tumor-informed molecular residual disease test. Tempus reported 9,000 MRD tests in Q2, while Personalis generated $22.357M in revenue and delivered 10,384 clinical

$TEMMedAI 8/10

Tempus Receives FDA Clearance for its AI Product Intended to Detect Signs of Pulmonary Hypertension From Standard ECGs

Tempus AI, Inc. (NASDAQ: TEM) received FDA clearance for its AI product, Tempus ECG-PH, designed to detect signs of pulmonary hypertension from standard ECGs. This is the third FDA-cleared cardiovascular device in Tempus' portfolio, aiming to help clinicians identify at-risk patients earlier. The product analyzes ECG data but is not intended for standalone diagnosis.

$TEMHighAI 8/10

Why Tempus AI Skyrocketed This Week

Tempus AI (TEM) shares rose 39.5% this week after Merck and Moderna reported positive Phase 3 trial data for their cancer vaccine, which uses technology from Personalis, a company Tempus is acquiring. Tempus's market cap is $13B, and its stock is still down about 10% over the past year. The acquisition is expected to close late 2024 or early 2027.

$PSNLHighAI 8/10

Personalis Stock Jumps As Tempus AI Acquisition Reshapes Outlook

Personalis Inc. (PSNL) stock rose 9.41% after reporting Q2 revenue of $22.4M, exceeding consensus estimates. The company agreed to be acquired by Tempus AI for $16.25 per share. Clinical volume for its NeXT Personal MRD test surged 199% year over year, with guidance for over 500% clinical revenue growth in 2026. Management will halt guidance and earnings calls as the company pivots to a merger-driven setup.